Managing cardiotoxicity in anthracycline-treated breast cancers

e12592 Background: The aim of the study is to assess the results of the treatment of 737 consecutive patients with DCIS with particular attention to the character of recurrences, other neoplasms and causes of deaths. Methods: A retrospective analysis was carried out of 737 consecutive DCIS patients treated in one institution in the years 1996-2011. The percentage of failures, causes of death, cumulated recurrence risk, DFS, OS depending on the method of treatment (mastectomy, breast conserving treatment BCT, breast conserving surgery BCS), was calculated. Results: 66 recurrences (42% DCIS, 58% invasive) were reported: 61 recurrences in the breast, 5 outside the breast. The comparison of mammography images before the initial treatment and after local recurrence revealed the true recurrence in the breast in 48/61 (79%) of cases. The cumulated recurrence risk after 15-year observation, after mastectomy, BCT and BCS was 3.2%, 19.5% and 31.2 %, respectively (p < 0.001). 15-year DFS after mastectomy, BCT and BCS was 72%, 65% and 48%, respectively (p < 0.001). 15-year OS after mastectomy, BCT and BCS was 75%, 83% and 70%, respectively, p = 0.329. In the course of the whole observation period 124 other neoplastic lesions in 121 patients (16%) were reported including 58 (8%) contralateral breast cancers. Deaths due to DCIS progression were reported in 4 (0.5%) of patients. An overwhelming majority (74/86) of deaths was linked to the age of the patients or other diseases, including other neoplasms. Conclusions: The highest recurrence risk reported in patients after BCS was unacceptable and, moreover, it kept growing over the fifteen years of observation. 79% of recurrences in the treated breast were true recurrences. Local recurrences were effectively treated without influence on OS. The percentage of deaths due to DCIS was low.

Download Full-text

Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers

Breast Cancer Research and Treatment ◽

10.1007/s10549-009-0479-x ◽

2009 ◽

Vol 121 (2) ◽

pp. 347-354 ◽

Cited By ~ 26

Author(s):

Lindsay A. Brown ◽

Karynn Johnson ◽

Samuel Leung ◽

Tarek A. Bismar ◽

Javier Benítez ◽

...

Keyword(s):

Adverse Outcome ◽

Breast Cancers ◽

Er Positive ◽

Treated Breast

Download Full-text

Hypercalcemia and treated breast cancers: The diagnostic dilemma

Journal of Cancer Research and Therapeutics ◽

10.4103/0973-1482.48770 ◽

2009 ◽

Vol 5 (1) ◽

pp. 46 ◽

Cited By ~ 2

Author(s):

Vishal Rao ◽

Devendra Chaukar ◽

AnilK D'Cruz

Keyword(s):

Breast Cancers ◽

Diagnostic Dilemma ◽

Treated Breast

Download Full-text

Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy

SpringerPlus ◽

10.1186/s40064-015-0851-8 ◽

2015 ◽

Vol 4 (1) ◽

Cited By ~ 2

Author(s):

Yoko Omoto ◽

Takashi Takeshita ◽

Yutaka Yamamoto ◽

Mutsuko Yamamoto-Ibusuki ◽

Mitsuhiro Hayashi ◽

...

Keyword(s):

Immunohistochemical Analysis ◽

Breast Cancers ◽

Estrogen Deprivation ◽

Treated Breast

Download Full-text

Methylated PLK2 is a prognostic biomarker in taxane-treated breast cancers

Discussion of Clinical Cases ◽

10.5430/dcc.v7n2p7 ◽

2020 ◽

Vol 7 (2) ◽

pp. 7

Author(s):

Priti Chivers ◽

Laura Lattanzio ◽

Ornella Garrone ◽

Daniela Vivenza ◽

Nel Syed ◽

...

Keyword(s):

Breast Cancer ◽

Promoter Methylation ◽

Cpg Island ◽

Progression Free Survival ◽

Predictive Biomarker ◽

Breast Cancers ◽

Kaplan Meier ◽

Treated Breast ◽

Neo Adjuvant Chemotherapy ◽

Drug Responsiveness

Background: In search of potential biomarkers of drug responsiveness the tumour suppressor PLK2 has been identified as a mediator of taxane sensitivity in some tumour types, based on its role of G2M checkpoint regulation.Objective: The current study set out to evaluate PLK2 methylation in breast cancer treated with neo-adjuvant chemotherapy including a taxane, as a biomarker of disease progression.Methods: Silencing of PLK2 in MCF-7 cells followed by taxane treatment was assessed using apoptotic readout for proof of principle. DNA was extracted from 64 cases of diagnostic surgical FFPE sections. Using pyrosequencing, levels of PLK2 promoter methylation were measured.Results: Silencing of PLK2 resulted in a significantly reduced apoptotic response following paclitaxel treatment (compared with scramble transfected controls). An association with higher levels of CpG island promoter methylation was seen for those cases with a progression-free survival (PFS) of less than 12 months. Kaplan-Meier analysis showed there was an association between overall survival (OS) and level of methylation (p = .06).Conclusions: Thus, based on data obtained from this pilot study, further larger studies evaluating the utility of PLK2 methylation as a potential predictive biomarker in breast cancer are warranted.

Download Full-text

Correlation of mRNA for oestrogen receptor beta splice variants ERβ1, ERβ2/ERβcx and ERβ5 with outcome in endocrine-treated breast cancer

Journal of Molecular Endocrinology ◽

10.1677/jme.1.01574 ◽

2004 ◽

Vol 33 (3) ◽

pp. 773-782 ◽

Cited By ~ 26

Author(s):

M P A Davies ◽

P A O’Neill ◽

H Innes ◽

D R Sibson ◽

W Prime ◽

...

Keyword(s):

Breast Cancer ◽

Oestrogen Receptor ◽

Splice Variants ◽

Nodal Status ◽

Endocrine Treatment ◽

Breast Cancers ◽

Treated Breast ◽

Post Menopausal ◽

Independent Marker ◽

Receptor Beta

This study has been performed to test the hypothesis that different oestrogen receptor beta (ERβ) splice variants may be important determinants of clinical parameters, including outcome, in post-menopausal women with breast cancer receiving adjuvant endocrine treatment but no chemotherapy. Splice variants ERβ1, ERβ2 and ERβ5 have been analysed by semi-quantitative RT-PCR in a cohort of 105 patients with primary breast cancer. Clinical correlates included age, grade, size, nodal status, ERα, progesterone receptor, Ki67, relapse-free survival (RFS) and overall survival (OS). Seventy per cent of cases were ERβ1 positive, 69% ERβ2 positive and 70% ERβ5 positive. Within the cohort, 47% were positive for all three variants while 10% were negative for all three. ERβ1 exhibited no discernible relationship with disease outcome. ERβ2 and ERβ5 expression was significantly associated with better RFS (P<0.005), and ERβ2 with better OS (P=0.0002). In multivariate analysis, ERβ2 (P=0.006), nodal status and the level of Ki67 expression were independent predictors for RFS while ERβ2 (P=0.0008) and Ki67 status were independent predictors for OS. In the ERα-positive cases, or in the subset of those receiving adjuvant tamoxifen, ERβ2 was significantly associated with good RFS (P<0.0005) and was the only independent marker of OS. We conclude that precise identification of splice variants of ERβ are more important assessors than is ERβ1 alone of the biological status of individual breast cancers, and hence in predicting their response to endocrine therapy.

Download Full-text

Ductal Carcinoma In Situ: What Can We Learn from Clinical Trials?

International Journal of Surgical Oncology ◽

10.1155/2012/296829 ◽

2012 ◽

Vol 2012 ◽

pp. 1-7

Author(s):

Lucio Fortunato ◽

Igor Poccia ◽

Ugo de Paula ◽

Elena Santini

Keyword(s):

Ductal Carcinoma In Situ ◽

Carcinoma In Situ ◽

Retrospective Studies ◽

Ductal Carcinoma ◽

Conservative Surgery ◽

Adjuvant Radiation ◽

Breast Cancers ◽

Treated Breast ◽

Clinical Conditions

Ductal Carcinoma in situ has been diagnosed more frequently in the last few years and now accounts for approximately one-fourth of all treated breast cancers. Traditionally, this disease has been treated with total mastectomy, but conservative surgery has become increasingly used in the absence of unfavourable clinical conditions, if a negative excision margin can be achieved. It is controversial whether subgroups of patients with favourable in situ tumors could be managed by conservative surgery alone, without radiation. As the disease is diagnosed more frequently in younger patients, these issues are very relevant, and much research has focused on this topic in the last two decades. We reviewed randomized trials regarding adjuvant radiation after breast-conservative surgery and compared data with available retrospective studies.

Download Full-text